<!-- What Is BPC-157? Sequence, Identifiers and the State of the Research | https://bpc157pens.com/what-is-bpc-157/ -->

Guide · The molecule

# What is _BPC-157?_

**BPC-157 (Body Protection Compound 157) is a synthetic peptide made of 15 amino acids.** It is modeled on a fragment of a larger protein found in human gastric juice and was first described by a research group at the University of Zagreb in Croatia.[2](#src-2)

By the bpc157pens.com Editorial Team · Last reviewed November 15, 2026

Sequence

## G·E·P·P·P·G·K·P·A·D·D·A·G·L·_V_

Fifteen residues joined by fourteen peptide bonds. The four prolines are part of why researchers describe the peptide as unusually stable.

[Video: One-minute hyperreal film of BPC-157 forming: glass spheres with glowing gold cores join one at a time into a single 15-sphere chain on a porous resin bead](https://bpc157pens.com/media/film-chain.mp4)

One minute, no sound. Press play to see each amino acid named as it joins, valine first and glycine last. Artistic visualization. Each sphere stands for one amino acid.

1.  01GlyG
2.  02GluE
3.  03ProP
4.  04ProP
5.  05ProP
6.  06GlyG
7.  07LysK
8.  08ProP
9.  09AlaA
10.  10AspD
11.  11AspD
12.  12AlaA
13.  13GlyG
14.  14LeuL
15.  15ValV

## BPC-157 _identifiers_

BPC-157’s molecular formula is C62H98N16O22 and its molecular weight is 1419.5 g/mol. Its CAS registry number is 137525-51-0.[1](#src-1)

Source: PubChem CID 9941957

|  |  |
| --- | --- |
| Full name | Body Protection Compound 157 |
| Other names | PL 14736, Bepecin, stable gastric pentadecapeptide BPC 157 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| One-letter code | GEPPPGKPADDAGLV |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.5 g/mol |
| CAS number | 137525-51-0 |

## What has lab research _studied?_

Published BPC-157 research is almost entirely in cell cultures and animals, mostly rats. These are laboratory findings, not evidence of effects in people.

Selected peer-reviewed studies

| Topic | Model | Reported finding | Source |
| --- | --- | --- | --- |
| Tendon cell behavior | Rat tendon cells, in the lab | Faster outgrowth and migration of tendon cells, linked to the FAK–paxillin pathway | Chang et al., 20114 |
| Growth hormone receptor | Rat tendon cells, in the lab | Increased growth hormone receptor expression | Chang et al., 20145 |
| Blood-vessel growth | Chick embryo membrane, human endothelial cells, rats | More vessel formation, associated with VEGFR2 activation | Hsieh et al., 20176 |
| Wound-healing models | Rats | Reported effects across many rat injury models | Seiwerth et al., 20213 |
| How the body processes it | Rats and beagle dogs | Elimination half-life under 30 minutes | He et al., 20227 |

A large share of the animal research comes from one group, led by Predrag Sikirić at the University of Zagreb.[2](#src-2) Independent replication is limited.

## How strong is the _evidence?_

Weak, for humans. A 2025 systematic review found 36 relevant studies, 35 preclinical and one clinical.[8](#src-8) A 2026 review found three human studies with 30 participants in total and rated the certainty as very low.[9](#src-9)

1.  Cell studiesMany. What the peptide does to cells in a dish.
2.  Animal studiesMost of the literature. Largely rats, largely one group.
3.  Human studiesThree small, uncontrolled reports: a 16-person chart review, a 12-person pilot and a 2-person safety pilot.[10](#src-10)–[12](#src-12)
4.  Controlled human trialsNone published.

The 2026 review judged all three human studies to be of poor quality and concluded BPC-157 should not be used in people outside regulated clinical trials.[9](#src-9) [The 20 studies behind this summary, with a plain-language note on each →](/bpc-157-research/)

## Open safety _questions_

-   **No clinical safety data.** Reviewers found no controlled data on safety in people.[8](#src-8)
-   **Blood-vessel growth.** The pro-angiogenic effect seen in lab studies raises a theoretical tumor-growth concern that has not been ruled in or out.[6](#src-6),[13](#src-13)
-   **Product quality.** Peptides sold online may not contain what the label says, which is why lot-specific testing matters.[14](#src-14)

## Sources

Study authors are credited for their published research. None of them wrote, reviewed or endorsed this site.

1.  National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957, BPC-157. [pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/9941957)
2.  Sikirić P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response. _Gut Liver_. 2020;14(2):153–167. [PMID 31158953](https://pubmed.ncbi.nlm.nih.gov/31158953/)
3.  Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. _Front Pharmacol_. 2021;12:627533. [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/)
4.  Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. _J Appl Physiol_. 2011;110(3):774–780. [PMID 21030672](https://pubmed.ncbi.nlm.nih.gov/21030672/)
5.  Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. _Molecules_. 2014;19(11):19066–19077. [PMID 25415472](https://pubmed.ncbi.nlm.nih.gov/25415472/)
6.  Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. _J Mol Med_. 2017;95(3):323–333. [PMID 27847966](https://pubmed.ncbi.nlm.nih.gov/27847966/)
7.  He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. _Front Pharmacol_. 2022;13:1026182. [PMID 36588717](https://pubmed.ncbi.nlm.nih.gov/36588717/)
8.  Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. _HSS J_. 2025;21(4):485–495. [PMID 40756949](https://pubmed.ncbi.nlm.nih.gov/40756949/)
9.  Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. _Acta Orthop Belg_. 2026;92(3). [PMID 42885452](https://pubmed.ncbi.nlm.nih.gov/42885452/)
10.  Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. _Altern Ther Health Med_. 2021;27(4):8–13. [PMID 34324435](https://pubmed.ncbi.nlm.nih.gov/34324435/)
11.  Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. _Altern Ther Health Med_. 2024;30(10):12–17. [PMID 39325560](https://pubmed.ncbi.nlm.nih.gov/39325560/)
12.  Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. _Altern Ther Health Med_. 2025;31(5):20–24. [PMID 40131143](https://pubmed.ncbi.nlm.nih.gov/40131143/)
13.  Cleveland Clinic. What you need to know about BPC-157. October 2026. [health.clevelandclinic.org](https://health.clevelandclinic.org/bpc-157-peptide)
14.  Harvard T.H. Chan School of Public Health. Peptides are all over social media and the news. Here’s what to know about them. [hsph.harvard.edu](https://hsph.harvard.edu/news/peptides-are-all-over-social-media-and-the-news-heres-what-to-know-about-them/)
